VolitionRX Ltd (VNRX) - Medical Equipment - Deals and Alliances Profile
October 2018
65
About the Report
About the Report
Summary
VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of various conditions including colorectal cancer, prostate and lung cancers, and inflammatory and other diseases. VolitionRX also conducts research and development, and offers clinical trial services. The company has collaboration with hospital, medical center, universities and research institute. It operates in Belgium, Singapore, the UK and the US. VolitionRX is headquartered in Singapore City, Singapore.
VolitionRX Ltd (VNRX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
VolitionRX Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
VolitionRX Ltd, Medical Equipment, Deal Details 11
Partnerships 11
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11
VolitionRx Enters into Distribution Agreement with Active Motif 12
VolitionRx Enters into Co-Development Agreement with University of Oxford 13
VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14
VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15
Equity Offering 16
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24
VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25
VolitionRx Raises USD14.1 Million in Public Offering of Shares 27
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29
VolitionRx Completes Private Placement Of Shares For USD 3 Million 31
VolitionRX Completes Private Placement Of Shares For USD 0.6 Million 32
VolitionRX Completes Private Placement Of Shares For USD 0.4 Million 33
VolitionRX Completes Private Placement Of Shares For USD 0.5 Million 34
VolitionRX Completes Private Placement Of Shares For USD 1 Million 35
VolitionRX Completes Private Placement Of Units For USD 1.2 Million 36
Acquisition 37
ValiRx Divests Its Stake In VolitionRx For USD 0.6 Million 37
VolitionRX Ltd-Key Competitors 38
VolitionRX Ltd-Key Employees 39
VolitionRX Ltd-Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Sep 19, 2017: VolitionRx Announces its European Colorectal Cancer Strategy 41
Financial Announcements 42
Aug 13, 2018: VolitionRx announces second quarter 2018 financial results and business update 42
May 10, 2018: VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update 44
Nov 09, 2017: VolitionRx Announces Third Quarter 2017 Financial Results and Business Update 45
Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 47
May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 48
Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 49
Corporate Communications 50
Mar 07, 2018: VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board 50
Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 51
Product News 52
Feb 26, 2018: VolitionRx Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer 52
Feb 05, 2018: VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark 54
Sep 14, 2017: Volition Granted Four Additional Patents 55
Jun 30, 2017: Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress 56
May 18, 2017: A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q assays 57
Other Significant Developments 58
May 09, 2018: VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits 58
Mar 01, 2018: VolitionRX Announces Full Fiscal Year 2017 Financial Results and Business Update 59
Sep 22, 2017: VolitionRx Announces the Initial Sale of its New Nu.Q Research Kits 61
Sep 21, 2017: VolitionRx Limited Awarded USD 1.5 Million in Non-Dilutive Funding 62
Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 63
Mar 28, 2017: Volition America Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
List of Figure
List of Figures
VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List of Table
List of Tables
VolitionRX Ltd, Medical Equipment, Key Facts, 2017 2
VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Deals By Market, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11
VolitionRx Enters into Distribution Agreement with Active Motif 12
VolitionRx Enters into Co-Development Agreement with University of Oxford 13
VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14
VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24
VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25
VolitionRx Raises USD14.1 Million in Public Offering of Shares 27
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29
VolitionRx Completes Private Placement Of Shares For USD 3 Million 31
VolitionRX Completes Private Placement Of Shares For USD 0.6 Million 32
VolitionRX Completes Private Placement Of Shares For USD 0.4 Million 33
VolitionRX Completes Private Placement Of Shares For USD 0.5 Million 34
VolitionRX Completes Private Placement Of Shares For USD 1 Million 35
VolitionRX Completes Private Placement Of Units For USD 1.2 Million 36
ValiRx Divests Its Stake In VolitionRx For USD 0.6 Million 37
VolitionRX Ltd, Key Competitors 38
VolitionRX Ltd, Key Employees 39
VolitionRX Ltd, Subsidiaries 40
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.